Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ombitasvir/paritaprevir/ritonavir - AbbVie/Enanta Pharmaceuticals

Next Previous
Drug Profile

Ombitasvir/paritaprevir/ritonavir - AbbVie/Enanta Pharmaceuticals

Alternative Names: ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); VIEKIRA XR; Viekirax

Latest Information Update: 19 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Amides; Anilides; Antiretrovirals; Antivirals; Aza compounds; Carbamates; Cyclopropanes; Phenanthridines; Pyrroles; Pyrrolidines; Small molecules; Sulfones; Thiazoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 19 Dec 2024 No development reported - Phase-III for Hepatitis C (Combination therapy, In adolescents, In children) in USA, Spain, Germany, Italy, Belgium, Puerto Rico (PO)
  • 25 Sep 2024 Regulatory submission withdrawn for Hepatitis C (Combination therapy) in Liechtenstein, Iceland, European Union, Norway (PO)
  • 27 Sep 2021 No development reported - Phase-III for Hepatitis C (Combination therapy) in Brazil (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top